Logo

Forte's FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis

Share this

Forte's FB-401 Fails to Meet Primary Endpoints in P-II Clinical Trial For the Treatment of Atopic Dermatitis

Shots:

  • The P-II clinical trial evaluates FB-401 vs PBO in patients with AD
  • The trial did not meet its 1EPs of EASI-50 (50% improvement in AD disease severity as measured by EASI)
  • Additionally- positive trends were identified in key 2EPs i.e.- improvement in disease severity @16wks.- patients achieving the EASI-90 EPs (27.6% vs 20.5%) while (38.2% vs 29.5%) in IGA success (2 point reduction and clear or almost clear). The 1EPs of EASI-50 was achieved in 58% vs 60% of patients

| Ref: Business Wire | Image: Forte Bioscience

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions